VOOPOO
20.4.2022 06:10:47 CEST | Business Wire | Press release
VOOPOO, leading vape brand, along with its sister brand ZOVOO, is looking forward to meeting you at the National Convenience Show Birmingham 2022 on April 25-27.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220414005472/en/
The National Convenience Show Birmingham is not only the largest retail show in the UK, but also the most professional world-class event in the world’s retail industry. This year, the event will gather 1,000+ global vendors to share cutting-edge consumer insights and commercial trends, and discuss hot topics such as technology, sustainable development, food hygiene and health, and social media. 90,000+ professional visitors are expected to visit the event.
As the leader of vape technology, VOOPOO and ZOVOO will feature three new products of the year in a 25sqm uniquely-designed booth and showcase new technological breakthroughs and smarter experience in the vape industry. On this occasion, VOOPOO looks forward to establishing connections with more excellent partners, peer brands and users, to jointly develop the market.
ARGUS GT 2, a member of VOOPOO’s high-end ARGUS series and the first MOD product in 2022, will be exhibited at the event. While inheriting the classic style of ARGUS GT, ARGUS GT 2 also provides a fully upgraded professional vape experience, a masculine aesthetic design and an improved collision-proof performance to satisfy massive clouds lovers and those vapers who pursue intensive explosion, high performance and high durability. It is poised to define a new height of user experience.
Powerful TPP vape platform, high power and massive clouds
ARGUS GT 2 is compatible with VOOPOO’s universal TPP vape platform, and with a maximum output power of 200W. The moment the ignition button is pressed, massive clouds will volcanically spew out, bringing users the ultimate enjoyment of taste and the strongest visual pleasure. In addition, with a 200W stable output, users are allowed to enjoy the luxurious experience in a leisurely manner.
Top water, dust and collision-proof body to withstand extreme outdoor scenarios
ARGUS GT 2 has obtained the IP68 rating, the highest rating of protection against water, dust and collision. After thousands of tests, the team for ARGUS GT 2 has created a powerful double-layer waterproof, dust-proof, frost-proof, and collision-proof body that can withstand various extreme outdoor environments like temperatures ranging from minus 20°C to 60°C without affecting its performance. Such a hard and durable ARGUS GT 2 will definitely become the best choice for outdoor vapers.
Innovative volcano crater design to guarantee both massive clouds and leak-proofness
Featured with massive clouds, ARGUS GT 2 comes with the MAAT TANK NEW, which has the unique two-way volcano crater airflow design that can increase the airflow rate by 60% and produce thicker clouds at a higher speed; at the same time, it can better drain the condensed liquid to the isolation section at the bottom, so as to create the ultimate leak-proof experience.
Top GENE.TT 2.0 chip to enable new experience of all-scenario intelligence
ARGUS GT 2 features GENE.TT 2.0 technology and is equipped with an upgraded smart chipset which can automatically match power, and supports multi-mode switching between Smart, RBA, Turbo and TC, allowing vapers to easily control their daily experience. In addition, it adopts a hidden 3A TYPE-C fast charging design, and the charging speed is also improved by 30%. VOOPOO products are rich in color and unique in design. ARGUS GT 2 to be displayed this time is no exception. It will offer five new colors including carbon fiber grey, lime green, and dark blue. This perfect fusion of technology and design will surely bring another surprise to the industry.
As a disruptor in the POD market, ZOVOO will bring DRAGBAR 600s, the first disposable vape with a light bar. The DRAGBAR series have been loved by global users since their launch. The innovative use of ethyl maltol to provide the sweetness in e-liquid can effectively avoid sugar addiction which causes harm to the human body, and are popular among vapers who favor sugar-free and low-sugar e-liquid. What kind of disruptive technology will the DRAGBAR 600s present at the show? In addition to ARGUS GT 2, what new surprises will VOOPOO's other two mysterious new products bring to the industry? Let's wait and see at Booth E20 of National Convenience Show Birmingham 2022 from April 25 to 27!
About VOOPOO
Founded in 2017, VOOPOO has rapidly grown and recognized by vapers from around the world with its DRAG series. VOOPOO is a high-tech enterprise integrating R&D, design, production and brand operation. It has four flagship product series: DRAG, VINCI, ARGUS and V Series, altogether providing consumers with a safe, reliable and diverse all-scenario product ecosystem. Currently, VOOPOO products are sold in more than 70 countries and regions in North America, Europe and Asia. VOOPOO will pursue long-term value and strengthen exchanges and cooperation in technology, brand, and supply chain, and promote the innovation and development of the vape industry. For more information, please visit https://www.voopoo.com/ and follow our Instagram, Facebook and TikTok.
WARNING: This product may be used with e-liquid products containing nicotine. Nicotine is an addictive chemical.
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220414005472/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom